Urgent eye problem? Same-day slots are held — call (609) 246-0236

info@khouryeyecare.com

Patient guide

Macular degeneration: what it is, what to watch for, and what helps

Call the same day if straight lines start to look wavy or bent, or a new blurry or dark spot appears in the center of your vision. These can be signs of the wet form, which is treated most successfully when treatment starts early. Call (609) 246-0236. A sudden loss of vision is an emergency: if the office is closed, or you cannot reach us, go to a hospital emergency room.

Age-related macular degeneration affects the macula, the small central part of the retina you use for reading, faces and driving. About 20 million Americans aged 40 and over have some form of it, and about one and a half million have the late stage.

In its early stages it typically causes no symptoms. Most people with early-stage disease keep good vision for years, and many never reach the advanced stage. The point of knowing is to catch the change that can be treated, quickly.

What it is

With age, small deposits called drusen can form under the macula. A few small drusen are a normal part of aging. Larger ones, or changes in the pigment under the macula, are the signs of macular degeneration, and they are what an exam looks for.

It affects the center of vision. It does not take away side vision.

The stages, and dry and wet

Early
Drusen beyond those of normal aging, with no symptoms. It is found at an eye exam, not by you.
Intermediate
Large drusen, or changes in the pigment under the macula. The risk of moving on to the late stage is markedly higher from here, and this is the stage at which eye vitamins have been shown to help.
Late, dry
Called geographic atrophy. Patches of the macula waste away, and central vision is lost as they grow toward the center.
Late, wet
Also called neovascular: new blood vessels form under the macula. This is the form that needs treatment quickly, and the reason for the weekly home check.

About eight in ten people with macular degeneration have the dry form. The wet form accounts for most of the severe vision loss. Dry disease can turn wet, which is why the warning signs matter even when you have been told yours is early.

What you notice

In the early and intermediate stages, usually nothing. Later:

  • Straight lines look wavy or bent.
  • A blurry or dark area in the center of what you are looking at.
  • Colors look less bright.

With both eyes open, a good eye can hide a problem in the other one. That is why the home check is done one eye at a time.

Who gets it

  • Age. It usually appears after 50, and most often after 60.
  • Smoking. The strongest risk factor you can change. Smoking about doubles the risk.
  • Family history. It runs in families. Brothers, sisters and children of someone who has it should have regular eye exams.
  • Ancestry. It is more common in white Americans than in Black or Hispanic Americans.

How it is found

Dilated exam
With the pupils widened, the macula can be examined directly for drusen and pigment changes. The stage is set from what is seen.
OCT scan
A scan that shows the layers of the retina in cross-section. You look into the instrument for a few seconds; there is no contact, no air puff and no dye.
Photographs
A record of how the macula looks today, so that the next visit can be compared with it.

These are done in this office. If a retina specialist is needed, your images and exam findings are sent ahead, so the specialist starts from what we already know.

What helps

  • Check each eye once a week. The grid and the instructions are on the page we give patients after their visit. If something looks different from last week, call the same day.
  • Do not smoke.
  • Take the AREDS2 vitamin formula only if your stage calls for it. It slowed progression in people with intermediate macular degeneration, or advanced disease in one eye. In early macular degeneration it has not been shown to help, so ask before buying. Many products sold as eye vitamins do not contain the AREDS2 formula.
  • If you smoke or used to, use only the AREDS2 version. The original formula contains beta-carotene, which raised the risk of lung cancer in current and former smokers. AREDS2 uses lutein and zeaxanthin instead. After ten years of follow-up, lutein and zeaxanthin showed no significant increase in lung cancer, and that group was 20% less likely to progress to late disease than the group given beta-carotene.
  • Eat leafy green vegetables and fish. Both are linked with lower risk in long-term studies.
  • Keep the interval set at your exam.

A home monitoring device has also been tested, in a randomized trial of people at higher risk of the wet form. Those who used it regularly had lost less vision by the time the wet form was found than those relying on other methods.

Treatment

Early and intermediate
No procedure. The work is the list above: the weekly check, not smoking, vitamins when your stage calls for them, and follow-up.
Wet
Injections into the eye, given by a retina specialist. The eye is numbed thoroughly and cleaned, and the medicine is injected in a few seconds. The injections are repeated, and the gap between them is lengthened in people who respond. For one of the current medicines, the FDA approved gaps of up to 20 weeks in April 2026; people who do not hold on a long gap go back to more frequent injections.
Geographic atrophy
Two injected medicines, pegcetacoplan and avacincaptad pegol, were approved in 2023, the first treatments for this stage. Given every one to two months, they slow the growth of the patches, by between about 14% and 35% in the trials depending on the medicine, the schedule and the length of treatment. They do not improve vision, and people who receive them have a higher risk of developing the wet form. Whether that trade is worth it is a decision to make with a retina specialist.
Light therapy
A light treatment for dry macular degeneration received FDA authorization in November 2024, for people whose vision is mildly reduced. It is given as nine sessions over three to five weeks, repeated every four months, and its cost is not covered by insurance.

When central vision has been lost, low vision services help people make the most of the sight they have.

Common questions

Will I go blind?

Macular degeneration does not take away side vision. Most people with early-stage disease keep good vision for years, and many never reach the advanced stage. What is at risk in the late stage is central vision, and protecting that is what the follow-up is for.

Should I start taking eye vitamins now?

Only if your exam shows intermediate disease, or advanced disease in one eye. In early macular degeneration the AREDS2 formula has not been shown to help. Ask at your visit which stage you are in before buying anything.

My parent had it. Should I be checked?

Yes. Macular degeneration runs in families, and brothers, sisters and children should have regular eye exams. Mention the family history when you book.

Do the injections hurt?

Most people feel pressure. The eye is numbed thoroughly and cleaned first, and the injection takes a few seconds. Some people have a scratchy, gritty feeling for a day afterwards. Increasing pain, redness or light sensitivity after an injection, or any drop in vision, is a same-day call to the retina office.

I take Ozempic or a similar medication. Does that matter?

One 2025 study linked these medications with the wet form in older adults with diabetes, and studies since then have been mixed. It is a reason to keep your follow-up visits, not a reason to stop the medication. GLP-1 medications and your eyes covers it.

Does this go through my vision plan or my medical insurance?

Vision plans cover routine exams and eyewear; medical insurance covers conditions, symptoms and monitoring. Vision plan or medical insurance explains how the reason for your visit decides which applies.

Call the office

If lines have started to look wavy or a spot has appeared in the center of your vision, call rather than book online, so you can be seen today.

Call (609) 246-0236

Khoury Eye Care, Hamilton Mall, 4403 Black Horse Pike, Mays Landing.

Sources

The figures and recommendations on this page come from the following. Ask at your visit if you would like a copy of any of them.

  1. American Academy of Ophthalmology Retina/Vitreous Preferred Practice Pattern Committee. Age-Related Macular Degeneration Preferred Practice Pattern. 2024 edition, published 2025.
  2. Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmology. 2022;140(12):1202-1208.
  3. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005-2015.
  4. Chew EY, Clemons TE, Agron E, et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 report 28. JAMA Ophthalmology. 2022;140(7):692-698.
  5. AREDS2-HOME Study Research Group. Randomized trial of a home monitoring system for early detection of choroidal neovascularization: Home Monitoring of the Eye (HOME) study. Ophthalmology. 2014;121(2):535-544.
  6. Heier JS, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023.
  7. Khanani AM, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402(10411):1449-1458.
  8. US Food and Drug Administration. Approvals of Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) for geographic atrophy, 2023; extended dosing intervals for Eylea HD (aflibercept 8 mg), April 2026; De Novo authorization of the Valeda light delivery system, November 2024.
  9. National Eye Institute. Age-related macular degeneration: risk factors and symptoms.